Poly Medicure has announced that an earnings conference call will be held on Monday, May 25, 2026, to discuss the audited financial results for the quarter and year ended March 31, 2026. The call is scheduled to commence at 5:00 PM India time pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Details

The management team will present the financial performance for Q4 and FY26. Key executives representing the company during the call include:

Access Information

Shareholders and analysts can join the conference call using the universal dial-in numbers provided. Registration for the Diamond Pass is available via a dedicated link. The coordinator for the event is Apoorv Rastogi.

Board Meeting Context

This earnings call follows the board meeting scheduled on the same day to consider and approve the audited financial results for the financial year ended March 31, 2026. The board is also scheduled to consider the recommendation of a final dividend, if any. The trading window for dealing in the company's securities remains closed until May 27, 2026.

Poly Medicure Limited has successfully completed the acquisition of Brazilian medical device company MEDYNEO COMERCIO DE PRODUTOS PARA SAUDE LTDA through its wholly owned subsidiary Polymed Brazil LTDA. The transaction was finalized on April 29, 2026, with the company receiving information about the completion on April 30, 2026.

Acquisition Structure and Timeline

Polymed Brazil LTDA executed a Quota Purchase Agreement on April 29, 2026, acquiring 100% equity in MEDYNEO from its existing quotaholders. The acquisition process was completed on the same day, with Polymed Brazil LTDA taking operational control of MEDYNEO, making it a step-down subsidiary of Poly Medicure Limited.

Target Company Profile

MEDYNEO COMERCIO DE PRODUTOS PARA SAUDE LTDA is a Brazilian limited liability company focused on the importation and commercialization of medical devices. The company was incorporated on July 24, 2025, and operates as a shell entity without past activities, operations, employees, or existing liabilities.

Strategic Rationale

The acquisition provides Poly Medicure with crucial market access capabilities in Brazil's medical device sector. MEDYNEO holds all necessary licenses, permits, and registrations required for legal operation in Brazil's medical device importation and commercialization business segment. This licensing framework enables Polymed Brazil LTDA to immediately commence commercial operations without the typical regulatory approval delays.

Regulatory Compliance

The transaction does not constitute a related party transaction, with no promoter or group company interests in the acquired entity. The acquisition required no governmental or regulatory approvals, streamlining the completion process. The company has disclosed the transaction under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring full regulatory compliance.

Market Expansion Impact

This acquisition represents Poly Medicure's strategic entry into the Brazilian medical device market through a clean corporate structure. By acquiring a company with established licensing but no operational history or liabilities, Poly Medicure gains immediate market access while maintaining operational flexibility for future business development in Brazil's growing healthcare sector.